3 May 2023 - Quviviq is indicated for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Idorsia today announced that Health Canada has granted marketing authorisation for Quviviq (daridorexant) for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, on 28 April 2023.

Read Idorsia press release